Kyntra Bio price to free cash flow KYNB

Market value divided by free cash flow over the last twelve months, since 2016.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 13.7×; Aug 2021
10-year median: 94.7×
10-year range: 13.0× to 342×
Peer median: 11.0×

Kyntra Bio's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Aug 2021, at 13.7×.

On the days it had one over the last ten years, its median was 94.7×, from 13.0× in Jul 2021 to 342× in Oct 2020.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2021	13.7×	13.0×	125×
2020	83.5×	83.5×	342×
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	306×	269×	306×
2016	316×	245×	316×

Against its peers

Companies in Drug Manufacturers - General nearest Kyntra Bio's size, closest first, today.

Company	Price to free cash flow
KYNBKyntra Bio	n/m
ATNMActinium Pharmaceuticals	n/m
SPROSpero Therapeutics	n/m
LFVNLifevantage	11.0×
Peer median	11.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Kyntra Bio

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.